Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174525
Status:
UNKNOWN
Last Update Posted:
2012-05-09
First Post:
2005-09-09
Brief Title:
Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimers Disease
Sponsor:
Pharmacology Research Institute
Organization:
Pharmacology Research Institute
Study Overview
Official Title:
A Phase IIA Multicenter Randomized Double-Blind Placebo-Controlled Multiple Ascending Dose Safety Tolerability Pharmacokinetic Pharmacodynamic and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
Status:
UNKNOWN
Status Verified Date:
2012-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study will assess whether AAB-001 is safe well tolerated and effective for use in patients with Alzheimers Disease AAB-001 is a new drug that is not available outside this study AAB-001 is an antibody a type of protein usually produced by white blood cells to destroy other substances in the body In Alzheimers disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion It is hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to remove it
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None